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Abstract
Background Hizentra® (IGSC 20 %) is a 20 % liquid IgG
product approved for subcutaneous administration in adults
and children 2 years of age and older who have primary im-
munodeficiency disease (PIDD). There is limited information
about the use of IGSC 20 % in very young children including
those less than 5 years of age.
Methods A retrospective chart review involved 88 PIDD in-
fants and children less than 5 years of age who received
Hizentra®.
Results The mean age at the start of Hizentra® was 34 months
(range 2 to 59 months). IGSC 20 % was administered weekly
to 86 infants (two additional infants received twice weekly
and three times weekly infusions, respectively) and included
an average of 63 infusions (range 6–182) for an observation
period up to 45.5 months. Infusion by manual delivery oc-
curred in 15 patients. The mean dose was 674 mg/kg/4 weeks.
The mean IgG level was 942 mg/dL while on IGSC 20 %,
compared to a mean trough IgG level of 794 mg/dL
(p < 0.0001) during intravenous or subcutaneous IgG admin-
istration prior to IGSC 20 %. Average infusion time was 47
(range 5–120) minutes, and the median number of infusion
sites was 2 (range 1–4). Local reactions were mostly mild and
observed in 36/88 (41 %) children. No serious adverse events
were reported. A significant increase in weight percentile
(7 % ± 19.2, p = 0.0012) among subjects was observed during
IGSC 20 % administration. The rate of serious bacterial infec-
tions was 0.067 per patient-year while receiving IGSC 20 %,
similar to previously reported efficacy studies.
Conclusions Hizentra® is effective in preventing infections,
and is well tolerated in children less than age 5 years.
Keywords Immunoglobulin . Subcutaneous .
Immunodeficiency . Children . Safety . Efficacy
Introduction
Primary immunodeficiency diseases (PIDD) confer increased
risk of recurrent respiratory, skin, and gastrointestinal infec-
tions [1–5]. Intravenous IgG replacement therapy (IVIG), in-
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dicated for patients with antibody deficiency, is common-
ly given every 3–4 weeks [6–10]. Subcutaneously-
administered IgG (SCIG) has increasingly been used as
alternative replacement therapy for PIDD patients
[11–15]. Because of low infusion volume and ease of
administration, SCIG is well suited for children.
Hizentra® (IGSC 20 %), a 20 % liquid SCIG formu-
lation, is approved for adults and children greater than
2 years of age with PIDD [16–21]. The higher concentration
allows a lower infusion volume and shorter infusion time.
Experience in children less than 5 years of age is limited
[22, 23].
We evaluated the efficacy and safety of IGSC 20 %
in children less than age 5 years. Because growth re-
striction in early childhood has been associated with a
high infectious disease burden [24–26], weight and
height percentiles during IGSC 20 % infusions were
assessed.
Table 1 Demographics, Characteristics, and Diagnosis for 88 PIDD Infants and Children at the Start of Hizentra®
Patient characteristic 34 Patients, Aged 0
to <2 Years, No. (%)
54 Patients, Aged 2
to 5 Years, No. (%)
88 Patients Total,
No. (%)
Gender, n (%)
Male 23 (26) 30 (34) 53 (60)
Female 11 (13) 24 (27) 35 (40)
Race, n (%)
White 29 (33) 41 (46) 70 (80)
Black or African American 4 (5) 4 (5) 8 (9)
Asian 1 (1) 3 (3) 4 (4)
Other 0 (0) 6 (7) 6 (7)
Age and Growth Parameters
Age, months, mean (range) 11 (2–23) 44 (25–59) 34 (2–59)
Height, cm, mean (range) 70.0 (50.6–91) 94.5 (76.3–116.5) 84.3 (50.6–116.5)
Weight, kg, mean (range) 8.7 (4.1–15.5) 15.0 (9.3–28.4) 12.5 (4.1–28.4)
Diagnosis, n (%)
T-cell and combined immunodeficiencies
Severe combined immunodeficiency 6 (6.8) 8 (9) 14 (16)
Hyperimmunoglobulin M syndrome 0 (0) 1 (1) 1 (1)
22q11 deletion 0 (0) 5 (5.7) 5 (5.7)
Ataxia-telangiectasia 0 (0) 2 (2) 2 (2)
Wiscott-Aldrich syndrome 1 (1) 0 (0) 1 (1)
Combined immunodeficiency, unspecified 3 (3.4) 0 (0) 3 (3.4)
Total 10 (11.4) 16 (18.2) 26 (29.6)
Predominantly antibody deficiencies
Common variable immunodeficiency 0 (0) 5* (6) 5* (6)
X-linked agammaglobulinemia 7 (8) 4 (4.5) 11 (12.5)
Immunoglobulin G subclass deficiency 0 (0) 2 (2) 2 (2)
Autosomal recessive agammaglobulinemia 0 (0) 1 (1) 1 (1)
Total 7 (8) 12 (14) 19 (22)
Disorders of innate immunity
NF-κB essential modulator (NEMO) 2 (2) 1 (1) 3 (3)
Total 2 (2) 1 (1) 3 (3)
Other
Hypogammaglobulinemia with specific antibody deficiency 1 (1) 7 (8) 8 (9)
Isolated Hypogammaglobulinemia with repeated infections 11 (12.5) 14 (16) 25 (28.4)
Transient hypogammaglobulinemia of infancy 2 (2) 2 (2) 4 (4.5)
Hyperimmunoglobulin E syndrome (STAT3) 0 (0) 2 (2) 2 (2)
Netherton syndrome 1 (1) 0 (0) 1 (1)
Total 15 (17) 25 (28) 40 (45)
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Methods
Patients
A retrospective review of Hizentra® replacement therapy was
performed in 88 infants and children under age 5 years
from 9 North American centers. Patients were included
if they received >1 dose of IGSC 20 % prior to age 5 years,
regardless of previous replacement. Patients with protein los-
ing conditions or concomitant treatment with IVIG while
on IGSC 20 % were excluded. Study data were man-
aged using Research Electronic Data Capture (REDCap)
program hosted at Carolinas Medical Center [27]. The
study was approved by the Institutional Review Board
at all participating institutions.
Efficacy and Safety Assessments
Study assessments included rates of serious bacterial
infections (SBIs) (bacteremia/sepsis, meningitis, pneu-
monias, osteomyelitis, septic arthritis, visceral abscess-
es), non-serious infections, adverse events (AEs), local
reactions, volume and duration of infusions, number of
infusion sites, and serum IgG levels [28]. Rate of infu-
sions was assessed for pump or manual delivery, and a
cut-off value of >20 ml/h was used for rapid delivery
based on previously published studies [13, 23, 29].
Growth Parameter Assessments
Weight and body length at the start and end of treat-
ment were recorded. Only patients with values at both
time points were included. Results were provided for all
patients, 4 subgroups described by gender and age at
start of Hizentra® (females ≤24 months, females >24–
59 months, males ≤24 months, and males >24–
59 months), and those who received hematopoietic stem
cell transplantation (HSCT, n = 15) or gene therapy (n = 1).
The difference in mean weight and length percentile was eval-
uated using a t-test. The analysis of covariancewas used to test
for sex differences.
Results
Study Population
Demographics and underlying PIDD diagnoses are shown
(Table 1). Fifty-three of the 88 infants were male and the most
common race was white. The predominant PIDD conditions in-
cluded T-cell or combined immunodeficiency (n = 26), pri-
mary antibody deficiency (n = 19), and isolated
hypogammaglobulinemia with repeated infections (n = 25). The
mean age at the start of Hizentra® was 34 (range 2–59) months.
Infusion Parameters
Most infants received weekly IGSC 20 % therapy (n = 86) for
1.5–45.5 (average 14.25) months, one was infused twice week-
ly (by pump) for 10.25months, and onewas infused three times
weekly (by manual delivery) for 8 months (Table 2). Seventy-
two of 88 patients received prior Ig therapy including 48 pa-
tients who received IVIG, and 24 patients who received SCIG
(Vivaglobin®, 16 %, CSL Behring). Sixteen patients (18 %)
were naïve to Ig therapy prior to starting Hizentra®.
Median cumulative monthly IGSC 20 % dosage was
674 mg/kg, compared to a monthly dosage of 552 mg/kg of
Ig prior to IGSC 20 % treatment. Infusion rates (Fig. 1) of
<20 ml/h occurred in 66/73 (90 %) (median 5.9 ml/h, range
1.3–18.9) subjects infused by pump compared to 5/15 (33 %)
(median 10 ml/h, range 7.5–12) subjects infused by manual
delivery, respectively. Rates >20 ml/h occurred in 7 of 73
(10 %) (median 20.6 ml/h, range 20–39.8) subjects infused
by pump compared to 10/15 (67 %) (median 29.7 ml/h, range
22.3–89.8) infused by manual delivery.
Of 46 patients receiving IVIG before being changed to
IGSC 20 %, 20 underwent dose adjustment by a factor of
1.53 (as recommended by the FDA) while 12 patients re-
ceived the same IVIG and IGSC 20 % dose and 9 patients
received a weekly dose lower than calculated for IVIG; 5
patients received dosing above the recommended 1.53 adjust-
ment factor. Mean IgG levels were higher for the 88 patients
receiving IGSC 20 % (942 mg/dL) compared to the 72 pa-
tients receiving IVIG or SCIG therapy prior to being switched
Table 2 Summary of 5572
Hizentra® Infusions for 88
Children
34 Patients, Aged
0 to <2 Years
54 Patients, Aged
2 to <5 Years
88 Patients Total
Median dosage, mg/kg/4 weeks (range) 753 (400–2000) 602 (260–2000) 674 (260–2000)
Mean number of infusions (range) 69 (10–182) 60 (6–137) 63 (6–182)
Mean infusion time, minutes (range) 49 (5–120) 46 (5–120) 47 (5–120)
Median number of infusion sites (range) 2.0 (1–3) 2.0 (1–4) 2.0 (1–4)
Mean volume per patient, mL (range) 8.3 (4–13) 11.2 (5–38) 10.1 (4–38)
Mean volume per site, mL (range) 4.5 (1.5–13.5) 5.7 (2.5–20.6) 5.2 (1.5–20.6)
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to IGSC 20% (794 mg/dL) (p < 0.0001). Thirty-three patients
had IgG levels for review during IVIG and subsequent IGSC
20 % administration: the mean IgG trough level on IVIG was
720 mg/dL while mean IgG level on IGSC 20 % was 943 mg/
dL (p < 0.0001, paired t-test).
For 72 patients who transitioned to Hizentra® from another
IgG therapy, reasons for change included difficult IV access
(n = 26), family/patient preference (n = 31), discontinuation of
prior product (Vivaglobin®) (n = 22), side effects (n = 5), trans-
portation problems (n = 3), more reliable dosing (n = 1), and
discontinuation of a peripherally-inserted central catheter (n = 1).
Sites of administration included thigh (58 %), abdomen
(24 %), thigh and abdomen (17 %), and arm and thigh
(1 %). Hizentra® was administered by pump (n = 73) or man-
ual delivery (n = 15). Manual delivery was most often accom-
plished using a 23-, 25-, or 27-guage butterfly needle set and
the mean volume per site was 4.7 mL (range 2.0–7.5 mL).
Needle length was reported in 55 patients and the most fre-
quently used size was 6 mm (80%), followed by 4 mm (15%)
and 9 mm (5 %). The median number of administration sites
was 2 (range 1–4 sites). After a short instruction phase,
Hizentra® was administered at home by a parent or caregiver
administered in all but two patients who received administra-
tion by a home care nurse or other provider.
Efficacy
The incidence of SBIs and non-serious infections per patient-
year (Table 3), respectively, were 0.067 and 0.29 during
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Fig. 1 Infusion rates for 88 pediatric patients receiving Hizentra® by
pump or manual delivery. Data are presented as the percentage of
patients and number of patients within each category
Table 3 Comparison of Number
and Rate of Infections Per Patient-
Year Occurring During Treatment
Prior to and during Hizentra®
(N = 88)
Prior to Hizentra®a Hizentra®
Infection Type Total
Number
of Infections
Rate of Infections
Per Patient-Year
Total
Number
of Infections
Rate of Infections
Per Patient-Year
Serious Bacterial Infections
Bacteremia/sepsis 20 0.09 3 0.03
Bacterial meningitis 2 0.01 0 0
Pneumonia, bacterial 42 0.20 3 0.03
Osteomyelitis/septic arthritis 0 0 1 0.01
Visceral abscess (liver,lung,brain) 3 0.01 0 0
Total 47 0.22 7 0.067
Non-Serious Infections
Urinary tract infection 8 0.04 0 0
Pneumonia, viral 10 0.05 3 0.03
Ear infection 6 0.03 3 0.03
Gastroenteritis 11 0.05 7 0.06
Abscess/cellulitis 8 0.04 4 0.04
Bronchiolitis/tracheitis 16 0.07 11 0.10
Sinusitis 1 0.005 3 0.03
Viremia (CMV, EBV) 6 0.03 0 0
Lymphadenitis 1 0.005 0 0
Fever 4 0.02 0 0
Other 6b 0.03 0 0
Total 77 0.37 31 0.29
a Includes 72 patients who received IVIG (n = 48) or SCIG other than Hizentra® (n = 24)
b Other infections included acute respiratory distress syndrome (n = 1), necrotizing enterocolitis (n = 1), necro-
tizing fasciitis of the chest wall (n = 1), Staphylococcus aureus peritonitis (n = 1), and infections site-not-specified
(Klebsiella, n = 1; Enterobacter, n = 1)
J Clin Immunol (2015) 35:558–565 561
Hizentra® administration, 0.22 and 0.37 prior to
Hizentra® administration (including 72 patients previ-
ously treated with Ig), and 0.25 and 0.40 prior to any Ig
therapy.
Tolerability
Replacement therapy with IGSC 20 % was well tolerated; 41
patients experienced no local AEs (Table 4). Local reactions
were mostly mild and observed in 36 children. Upper respira-
tory tract infections were reported in 15 (17 %) patients. Other
AEs included pruritus (n = 3), irritability (n = 3), and one
patient each with bronchitis, pyrexia, sinusitis, and otitis.
There were no serious AEs.
IGSC 20 % was discontinued in 14 (15.9 %) patients prior
to age 5 years. Reasons for discontinuation included resolved
immune deficiency (n = 6), physician discontinuation (n = 4),
parental refusal (n = 2), intolerance related to pruritus (n = 1),
and prolonged hospitalization following renal transplantation
(n = 1). One patient expired of unrelated causes.
Growth Parameter Assessments during Hizentra®
Weight and length percentiles were assessed at the beginning
and end of Hizentra® observation period. Among 85 patients
for whom weight parameters were available, there was a sta-
tistically significant increase in overall weight percentile with
a mean increase of 7 % (standard deviation [SD] = 19.2 %)
(p = 0.0012) (Fig. 2A-D) over the observation period (mean
Table 4 Summary of Adverse Events
Adverse Event 34 Patients,
Aged 0 to
<2 Years,
No. (%)
54 Patients,
Aged 2 to
<5 Years,
No. (%)
88 Patients
Total, No. (%)
None 20 (59) 21 (39) 41 (47)
Any adverse eventa 14 (41) 33 (61) 47 (53)
Local reactionb 9 (26) 27 (50) 36 (41)
Upper respiratory
tract infection
1 (3) 14 (26) 15 (17)
Pruritus 1 (3) 2 (4.7) 3 (3)
Bronchitis 0 (0) 1 (2) 1 (1)
Pyrexia 0 (0) 1 (2) 1 (1)
Sinusitis 0 (0) 1 (2) 1 (1)
Otitis media 0 (0) 1 (2) 1 (1)
Irritability 3 (9) 0 (0) 3 (3)
aMultiple adverse events occurred in some patients
b Based on 16 MedDRA preferred terms
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Fig. 2 (A-D): Weight percentile measurements are shown at the start and
completion of Hizentra® therapy for 86 patients. A and B include females
(<=24 and >24–59 months, respectively). C and D similarly show males
(<=24 and >24–59 months, respectively). Each line represents 1 patient,
and red diamonds ( ) represent mean weight percentile at first and last
measurement on Hizentra®
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427 days). Those with an initial weight below 30th percentile
saw the most significant gains. The largest increase in weight
percentile was in males ≤24 months with a mean of 18 %
(SD = 24) (p = 0.0009). Among 74 patients for whom length
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Fig. 3 (A-D): Length percentile measurements are shown at the start and
completion of Hizentra® therapy for 74 patients. A and B include females
(<=24 and >24–59 months, respectively). C and D similarly show males
(<=24 and >24–59 months, respectively). Each line represents 1 patient,
and red diamonds ( ) represent mean length percentile at first and last
measurement on Hizentra®
Table 5 Comparison of Changes
in Weight and Height Percentiles
Among Transplanted and Non-
transplanted Patients During
Treatment with Hizentra®
Change from Baseline
Weight Percentile Height Percentile
Group Transplant* Status N Mean (SD) N Mean (SD)
Male
≤ 24 months Transplant 4 8.0 (6.6) 4 2.3 (27.0)
No Transplant 20 20.3 (25.2) 18 10.7 (20.0)
Overall 24 18.2 (23.5) 22 9.2 (20.9)
> 24 months Transplant 6 −0.8 (26.3) 6 2.5 (9.3)
No Transplant 22 1.5 (17.7) 18 2.3 (14.2)
Overall 28 1.0 (19.3) 24 2.3 (12.9)
Female
≤ 24 months Transplant 3 19.7 (2.9) 3 −11.3 (20.0)
No Transplant 8 −2.4 (6.3) 7 −8.1 (19.4)
Overall 11 3.6 (11.6) 10 −9.1 (18.5)
> 24 months Transplant 3 −5.7 (9.0) 3 3.3 (5.8)
No Transplant 19 5.6 (10.7) 15 −2.7 (18.7)
Overall 22 4.0 (11.0) 18 −1.3 (17.3)
*Included patients who underwent hematopoietic stem cell transplantation (n = 15) or gene therapy (n = 1)
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parameters were available, there was an overall increase in
length percentile of 2 % (SD = 18), but this did not reach
statistical significance (p = 0.36) (Fig. 3A-D). The greatest
increase in length percentile occurred in males ≤24 months
with a mean of 9 % (SD = 21) (p = 0.052). For 16 patients
who underwent HSCT or gene therapy, smaller increases in
growth were seen compared to those who did not (Table 5).
The difference between males and females was statistically
significant for change in length (p = 0.018) but not weight
(p = 0.099) regardless of age at baseline.
Discussion
This is the first large retrospective study to examine efficacy
and safety of SCIG in very young children. In 88 children less
than 5 years of age, including 34 children less than 2 years of
age, Hizentra® was safe and efficacious with an annualized
rate of SBIs of 0.067 per patient-year. This rate is similar to
those observed in older children and adults [16, 17, 19–21].
Mean IgG levels were higher during IGSC 20 % administra-
tion (942 mg/dL) compared to IgG levels in the same cohort
during receipt of IVIG (794 mg/dL) (p < 0.0001). Higher
trough IgG levels are known to be associated with a signifi-
cant decrease in serious infections for PIDD patients [9]. The
higher mean dose of IGSC 20 % (674 mg/kg/4 weeks) com-
pared to IVIG may have been due to the converting factor of
1.53 or higher when switch from IVIG to IGSC 20 %. Higher
IgG serum levels (17–22%) on IGSC 20% compared to IVIG
have been previously reported [16, 17], and with equal dosing
1:1, SCIG will result in 13 % average high serum IgG levels
compared to IVIG [18]. However, most immunologists be-
lieve it is not necessary to give higher doses of Hizentra®
including those patients less than age 5 years.
Hizentra® was well tolerated in PIDD patients. Local reac-
tions were mostly mild. Systemic AEs were infrequent and
there were no serious AEs. Only one patient discontinued
treatment due to pruritus. Low rates (29 %) of local reactions
observed in children less than age 2 years may have been
related to lower infusion volumes [16, 17, 21]. Manual admin-
istration of IGSC 20 % in 15 (17 %) patients without a pump
device was tolerated without difficulty. Mean infusion time
(47 min) was less than that reported for IGSC 20 % in adoles-
cents (60 min) and adults (85 min) [17] and among children
and adults (76 min) [16]. This was likely related to smaller
volumes administered to smaller patients, and to some patients
who received rapid infusion by manual delivery.
Weight percentile among 85 subjects increased significant-
ly (7 %, p = 0.0012) during the observation period (mean
427 days), and those below the 30th percentile for weight
saw the largest gains. Similar observations have been reported
in young children during catch-up growth after a period of
high infectious disease burden or inadequate dietary intake
[24, 25, 30–32]. A smaller increase in length percentile was
observed (2 %) in 74 subjects, although this was not statisti-
cally significant. Previous observations suggest stunted
growth in children requires recovery in weight before resum-
ing linear growth [24, 30–32]. Perhaps a longer observation
period in the current study would have seen larger gains in
length percentiles. Patients receiving HSCT or gene therapy
had smaller gains in growth which may have been related to
complications associatedwith treatment, although this was not
assessed. Data from this study support the observation that
poor growth seen among PIDD patients, most likely related
to prior frequent and severe infections, can be reversed with
optimal immunoglobulin replacement.
In summary, Hizentra® was effective in preventing infec-
tions in PIDD infants and children less than age 5 years. Infu-
sions were associated with an overall increase in weight and
length percentiles. Hizentra® is well tolerated with no serious
adverse events and is suitable for immunoglobulin replace-
ment in very young children. Hizentra® may also be well-
suited for small pediatric patients in whom venous access is
difficult.
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